|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Barrier Therapeutics, Inc. (BTRX) Introduces New Xolegel Duo(TM) Offering at the American Academy of Dermatology Summer Academy Meeting 2007
8/2/2007
PRINCETON, NJ--(MARKET WIRE)--Aug 2, 2007 -- Barrier Therapeutics, Inc. (NasdaqGM:BTRX - News), a pharmaceutical company developing and commercializing products in the field of dermatology, is announcing the market introduction of Xolegel Duo(TM) today at the American Academy of Dermatology (AAD) Summer Academy Meeting 2007. Xolegel Duo is a complete system for the treatment of seborrheic dermatitis of the scalp, face, and body. Seborrheic dermatitis is a common, recurring skin inflammation characterized by a red, scaly, itchy rash primarily on the face, scalp, hairline, eyebrows and torso.
|
|
|
|
|
|
|
|
|
|
|
|